DOJ closes inquiry into Cassava Sciences; ends all government investigations

FILANA THERAPEUTICS, INC.

DOJ Fraud Section closed previously-disclosed inquiry into research misconduct allegations.
The related indictment in United States v. Wang was dismissed with prejudice on Oct 23, 2025.
Company previously settled SEC negligence charges in Sept 2024 with monetary penalty.
CEO Richard Barry says company remains focused on developing treatment for TSC-related epilepsy.
No further government investigations pending against Cassava Sciences.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.